Transcript COPD - University of California, Irvine

Chronic Obstructive Pulmonary Disease
Updated Guidelines and Newer Therapies
Heba Ismail, MD
Assistant clinical Professor
Division of Pulmonary and Critical Care Medicine
University of California, Irvine Medical Center
E-mail, [email protected]
Disclosure

None
Definition

The international Global initiative on Chronic
Obstructive Lung Disease (GOLD), (WHO/NIH
2009) defines COPD as:
◦ A preventable and treatable disease with some
significant extra-pulmonary effects that may
contribute to the severity in individual patients.
◦ The pulmonary component is characterized by
airflow limitation that is not fully reversible.
◦ The airflow limitation is usually progressive and
associated with an abnormal inflammatory response
of the lung to noxious particles or gases.
Definition

This definition no longer describes emphysema, or
chronic bronchitis.
◦ COPD is much more a small airways (< 2 mm) disease, pathologically a chronic
bronchiolitis caused predominantly by prolonged exposure to tobacco smoke.

Destructive alveolar wall rupture occurs from an
imbalance between elastases and anti-elastases, and
prolonged activation of inflammatory cells causing
regional elastin damage with alveolar emphysema.

Loss of lung elastic recoil is the key pathophysiological
finding, and occurs with emphysema perhaps before loss
of alveolar wall and surface area measurable by carbon
monoxide diffusing capacity (DLco).
COPD and Chronic Bronchitis

Chronic bronchitis per se is a smoking related disease of large
airways that often resolves after smoking cessation.

Patients with COPD who suffer from chronic bronchitis generally
show:
◦ Faster functional decline
◦ More exacerbations
◦ Greater morbidity and mortality

A greater percentage of smokers with chronic cough can have
COPD as compared with smokers without symptoms when
functionally reassessed after 8 years.

Chronic bronchitis can be considered as both a risk factor for
COPD, and a worse prognostic factor in the presence of COPD.
Pathology

Pathological changes of COPD are found in:
◦ Airways
◦ Lung Parenchyma
◦ Pulmonary Vasculature

Pathological changes include:
◦ Chronic Inflammation
◦ Structural changes
Pathogenesis
Pathogenesis
Oxidative Stress
 Protease-Antiprotease Imbalance
 Inflammatory cells
 Inflammatory Mediators

Pathophysiology

Pathologically, COPD is characterized by two
distinct and frequently coexisting aspects:
◦ Small airway abnormalities --- will contribute to
airflow limitation by narrowing and obliterating the
lumen and by actively constricting the airways,
therefore increasing the resistance---decreased FEV1
◦ Parenchymal destruction (or emphysema)--- airflow
limitation and decreased gas transfer
Pathophysiology

Collapse of small airways during expiration lead to
further static hyperinflation.

These early changes are not detectable by simple
pulmonary function tests (PFT)

Reliance on the FEV1/FVC < 0.70 and FEV1 % of
predicted remains the current state of the art in COPD
screening and staging.

A normal DLco does not rule out COPD.
Pathophysiology

Airflow limitation and Air Trapping

Gas Exchange Abnormalities

Mucus Hypersecretion

Pulmonary Hypertension

Systemic Features
COPD

No blood test, imaging study, or lung function can
completely describe impairment from COPD.

The BODE Index is a valuable tool
 Predicting survival in clinical research
 Assessing disease burden and impairment utilizing
Body mass index (BMI)
◦ FEV1 expressed as % of predicted
◦ Severity of dyspnea (the cardinal symptom of COPD)
◦ Exercise capacity or 6-minute walk distance (6MWD)
Epidemiology

The prevalence of COPD varies by country
 It is generally linked to the prevalence of tobacco smoking
 There is also a link to air pollution from the burning of wood and other biomass
fuels

Worldwide, COPD is one of the leading cause of morbidity and
mortality

COPD is the 4th leading cause of mortality in the USA, and is also
the only one of the top five leading causes of death that is
continuing to rise, doubling from 1970 to 2002

It is projected that COPD will become the third leading cause of
death worldwide by 2020

COPD deaths among women in the USA have been rapidly rising
since the 1970s and have exceeded male COPD deaths since 2000
Epidemiology

COPD presents an increasing social and economic burden.

COPD patients incur health care costs associated with
frequent clinic visits, urgent care visits, and hospitalizations.

Home medical therapies, including oxygen therapy, visiting
nursing services, and rehabilitation add to the cost .

The health-care expenditure for each COPD patient cost on
average $6,000 annually.

In 2002, the estimated USA direct medical cost of COPD
was $18 billion while indirect costs including lost wages and
decreased productivity were estimated at $14.1 billion.
COPD phenotypes
Asthma-COPD overlap syndrome
 Exacerbators
 Emphysema-Hyperinflation

◦ Chronic Bronchitis can accompany any of the three
phenotypes
Proportional Venn diagram presenting the different phenotypes within the Wellington Respiratory Survey study population. The large
black rectangle represents the full study group. The clear circles within each coloured area represent the proportion of subjects with
COPD (post-bronchodilator forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) <0.7). The isolated clear circle represents
subjects with COPD who did not have an additional defined phenotype of asthma, chronic bronchitis or emphysema. (Reproduced with
permission from Marsh SE, Travers J, Weatherall M et al. Proportional classifications of COPD phenotypes. Thorax 2008; 63: 761-767.)
COPD Classification

GOLD has classified COPD into four
stages based on spirometric values and
thus on severity of airflow obstruction
(Table 1) .
Table 1
Classification of COPD
COPD, Management

The focus of COPD treatment should be
◦
◦
◦
◦
◦
Relief of symptoms
Improving exercise tolerance and overall health status
Prevention and timely treatment of exacerbations
Preventing disease progression
Reducing mortality .
COPD Management
Non pharmacotherapy
 Pharmacotherapy
 Surgery
 Minimally Invasive Surgery

Smoking Cessation

The Global Initiative for Chronic
Obstructive Lung Disease (GOLD)
guidelines emphasize that smoking
cessation is, “the single most effective and
cost-effective way to reduce exposure to
COPD risk factors”.
Pulmonary Rehabilitation

According to the ATS statement on pulmonary rehabilitation,
it is defined as a
◦ “Multidisciplinary program of care for patients with chronic
respiratory impairment that is individually tailored and designed
to optimize physical and social performance and autonomy”
◦ Pulmonary rehabilitation improves quality of life, by improving
exercise tolerance, and dyspnea.
◦ Pulmonary rehabilitation was found to increase peak workload
by 18%, and peak oxygen consumption by 11%.

Pulmonary rehabilitation should be considered for COPD
patients with reduced exercise tolerance and limitation of
their daily activities secondary to their disease.
COPD, Pharmacotherapy
◦ Pharmacologic therapy is able to significantly
improve the quality of life and reduce the
frequency of exacerbations
BUT
◦ Unable to halt the annual decline in FEV1 or
unequivocally reduce mortality, with the
important exception of oxygen therapy where
indicated.
Oxygen Therapy

Long-term oxygen therapy (more than 15 hours
a day) has been shown to
◦ Improve survival
◦ Exercise tolerance
◦ Pulmonary hemodynamics including pulmonary artery pressure,
lung mechanics and mental status.

Indications of long term oxygen therapy include:
◦ PaO2 at or below 55 mmHg or/ SaO2 of less than or equal to
88%
◦ PaO2 between 55 mmHg and 60 mmHg, SaO2 of 89% if there is
evidence of pulmonary hypertension, peripheral edema
suggesting congestive heart failure or polycythemia.
Pharmacotherapy
 Bronchodilators
◦ They do not alter the decline in lung function.
◦ They decrease expiratory trapped air volume
and reduce dynamic hyperinflation during
exercise as well as at rest.
◦ They are prescribed in both short- and longacting forms for immediate (rescue) and
sustained relief, respectively.
Pharmacotherapy

Long-acting bronchodilators are recommended for
patients with moderate to severe COPD.

In the largest trial of a Salmeterol, long-acting beta-2
agonist (LABA), Toward a Revolution in COPD Health
(TORCH), patients with a mean forced expiratory
volume in one second (FEV1) of 44% of predicted were
randomly assigned to one of four treatment arms for 3
years:
◦
◦
◦
◦
Salmeterol alone (50 mcg twice daily)
Fluticasone alone (500 mcg twice daily)
Combination of both
Placebo
Pharmacotherapy

The Salmeterol alone and combination arms each
revealed improved lung function, health-related
quality of life, and reduced exacerbation rates
compared to the placebo arm.

No statistically significant mortality reduction was
seen.

However, the combination of Fluticasone and
Salmeterol showed a trend towards a significant
reduction of all-cause mortality by 17.5% in 3
years compared to placebo.
TORCH
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Peter M.A. Calverley, M.D., Julie A. Anderson, M.A., Bartolome Celli, M.D., Gary T. Ferguson, M.D., Christine Jenkins, M.D., Paul W. Jones, M.D., Julie C. Yates, B.S., and Jørgen
Vestbo, M.D. for the TORCH investigators
N Engl J Med 2007; 356:775-789February 22, 2007DOI: 10.1056/NEJMoa06307
Pharmacotherapy

Tiotropium, was assessed in a randomized trial Understanding Potential
Long-Term Impacts on Function with Tiotropium (UPLIFT).

Among patients with moderate (45%) and severe (44%) COPD, Tiotropium
or placebo was added to ongoing care, that is, inhaled corticosteroids,
long-acting beta-2 agonists, and/or theophylline, for a duration of 4 years.

Tiotropium significantly reduced the risk of exacerbations and associated
hospitalizations and respiratory failure when added to usual care.

There was no difference in the annual rate of decline of FEV1 or mortality
between the two groups .

An intention-to-treat analysis that assessed mortality after 4 years, the use
of Tiotropium reduced all cause mortality by 13% (HR = 0.87, 95% CI
0.76–0.99, ).
Pharmacotherapy

The combination of bronchodilators of different classes and
durations may provide an improved effect with fewer side effects .

For example, the combination of a LABA and an anticholinergic
(Tiotropium) showed an improved FEV1 by the end of a 12-week
trial .

In another study, the use of a short acting beta-agonist plus an
anticholinergic showed a greater and longer-lasting FEV1
improvement when compared to each drug alone .

No clear data are available as to which long-acting bronchodilator
combination provides the best relief.

Current guidelines recommend weighing the risks and benefits of
each for the individual patient .
Pharmacotherapy

Although pulmonary inflammation plays an important
role in the pathophysiology of the disease, inhaled
corticosteroids (ICS) have not definitively been shown
to decrease the rate of lung function decline or change
COPD morbidity per se.

However, the addition of an ICS may prove beneficial for
some patients.
Pharmacotherapy

In the TORCH study, the combination of a LABA
plus ICS resulted in a decrease in the number of
exacerbations along with sustained benefits in
health status and sustained improvement in FEV1
when compared to Placebo, Salmeterol alone and
Fluticasone alone .

This combination is typically reserved for patients
with GOLD stages 3 and 4 with recurrent
exacerbations, or for those who have baseline
eosinophilic component of their disease or
associated asthma.
Pharmacotherapy

A recent meta-analysis readdressed the possibility of a
favorable effect on mortality when combining ICS and
bronchodilators in COPD.

Use of an ICS combined with LABA demonstrated a 20%
reduction in total mortality, with a mortality risk ratio of
0.80 (95% CI, 0.69–0.94).

However, use of a LABA or Tiotropium alone did not
decrease the mortality rate .

There is also concern that the use of high dose ICS in
patients with COPD may be associated with an increased
risk of pneumonia.
Therapy at Each Stage of COPD
I: Mild
II: Moderate
III: Severe
IV: Very Severe
FEV1/FVC < 70%
• FEV1/FVC < 70%
• FEV1/FVC < 70%
• FEV1 > 80%
predicted
• 50% < FEV1 <
80%
predicted
• FEV1 < 30%
predicted
• FEV1/FVC < 70% or FEV < 50%
1
predicted plus
• 30% < FEV1 <
chronic
50% predicted
respiratory failure
Active reduction of risk factor(s); influenza vaccination
Add short-acting bronchodilator (when needed)
Add regular treatment with one or more long-acting
bronchodilators (when needed); Add rehabilitation
Add inhaled glucocorticosteroids if
repeated exacerbations
Add long term
oxygen if chronic
respiratory failure.
Consider surgical
treatments
Novel Pharmacotherapy
Phosphodiesterase (PDE) Inhibitors
 N-Acetylcysteine (NAC)
 TNFα Inhibitors-Infliximab
 ABX-IL8
 Anti-leukotriene Drugs
 Prophylactic Use of Macrolides
 Vitamin D

Novel Pharmacotherapy

Inflammatory cells such as neutrophils, CD8 lymphocytes, and
macrophages, express predominantly phosphodiesterase (PDE)
type 4.

PDE type 4 hydrolyzes cyclic adenosine monophosphate (cAMP) in
inflammatory cells.

By inhibiting PDE type 4, intracellular cAMP concentrations
increase which leads to activation of protein kinase A,
phosphorylation and inactivation of target transcription factors,
which ultimately result in reduction of cellular inflammatory
activity.

While theophylline is a nonspecific PDE inhibitor (thus with a large
side-effect profile including diarrhea, seizures and cardiac
arrhythmias), several new drugs have been tested that target PDE
type 4 specifically, notably Cilomilast and Roflumilast
PDE-4
PDE-4 Inhibitors

The safety and efficacy of Cilomilast (15 mg twice daily)
was evaluated in
◦ A double-blind placebo-controlled study
◦ Significant increase in FEV1 as well as fewer exacerbations over a 24week period.

Gastrointestinal side effects (nausea and diarrhea) were greater in
the first 3 weeks of the study in the treatment arm.

Cilomilast has been evaluated in three additional multicenter,
randomized, placebo-controlled phase III trials.
◦ The change of FEV1 (from 30–40 mL) compared to placebo was significant in
only two of the four studies.

Overall, these studies did not show as large of improvements in
FEV1 as was expected based on phase II trials.
PDE-4 Inhibitors

Roflumilast is a more potent PDE type 4 inhibitor compared to
Cilomilast .

In a phase III multicenter placebo-controlled trial, 1411 patients
were randomly assigned to receive Roflumilast 250 mcg, Roflumilast
500 mcg, or placebo daily for 24 weeks.

Post-bronchodilator FEV1 at the end of treatment significantly
improved for both groups of Roflumilast when compared to
placebo (74 mL with the lower dose and 97 mL with the higher
dose medication).

Both groups suffered fewer mild exacerbations while moderate to
severe exacerbations were unchanged.

The most common side effects were also diarrhea and nausea.
PDE-4 Inhibitors

Two randomized clinical trials on the use of Roflumilast
compared to placebo were published in 2009.

Patients in these studies had COPD with severe airflow
obstruction, documented cough and sputum production,
and a history of frequent COPD exacerbations in the
past year.

In pooled analysis, the pre-bronchodilator FEV1
increased by 48 mL among those with the treatment
drug, a statistically significant improvement compared to
placebo.
PDE-4 Inhibitors

Moderate to severe exacerbations were also
significantly less in the treatment arm.

When compared to placebo, the addition of
Roflumilast to Salmeterol was associated with a
49 mL prebronchodilator FEV1 increase, and an
80 mL increase when added to Tiotropium

Side effects such as nausea, diarrhea and weight
loss contributed to greater patient withdrawal
Surgery and Minimally Invasive
(Non-Surgical) Approaches
Bullectomy
 Lung Volume Reduction Surgery
 Minimally Invasive approaches

◦
◦
◦
◦
Endobronchial Blockers
Bronchial Fenestration and Airways Bypass
Endobronchial Valves
Biological Lung Volume Reduction (Sealants)
Surgery for COPD
Bullectomy

Bullectomy appears to be of benefit in highly selected
patients resulting in short-term improvements in airflow
obstruction, lung volumes, hypoxaemia and hypercapnia,
exercise capacity, dyspnea, and health-related quality of life.

Surgical mortality ranges from 0-22.5%

Long-term follow-up data are more limited with 1/3-1/2 of
patients maintaining benefits for ~5 yrs

Patient selection
◦ most investigators have attempted to identify optimal surgical
candidates on the basis of pulmonary function and radiographic
features
Bullectomy
Patient Selection
Lung Volume Reduction Surgery
LVRS
LVRS, NETT

Methods
◦ A total of 1218 patients
with severe emphysema
underwent pulmonary
rehabilitation and were
randomly assigned to
undergo lung-volume–
reduction surgery or to
receive continued medical
treatment
LVRS, NETT
LVRS, NETT

Results
◦ Overall mortality was 0.11 death per person-year in both treatment
groups.
◦ After 24 months, exercise capacity had improved by more than 10 W in
15 percent of the patients in the surgery group, as compared with 3
percent of patients in the medical-therapy group (P<0.001).
◦ With the exclusion of a subgroup of 140 patients at high risk for death
from surgery according to an interim analysis, overall mortality in the
surgery group was 0.09 death per person-year, as compared with 0.10
death per person-year in the medical-therapy group (risk ratio, 0.89;
P=0.31).
◦ Exercise capacity after 24 months had improved by more than 10 W in
16 percent of patients in the surgery group, as compared with 3 percent
of patients in the medical-therapy group (P<0.001).
LVRS, NETT
◦ Among patients with predominantly upper-lobe
emphysema and low exercise capacity, mortality was
lower in the surgery group than in the medicaltherapy group (risk ratio for death, 0.47; P=0.005).
◦ Among patients with non–upper-lobe emphysema and
high exercise capacity, mortality was higher in the
surgery group than in the medical-therapy group (risk
ratio, 2.06; P=0.02).
LVRS, NETT

Conclusions
◦ Overall, lung-volume–reduction surgery
 Increases the chance of improved exercise
 It does yield a survival advantage for patients with both
predominantly upper-lobe emphysema and low base-line
exercise capacity.
 Patients previously reported to be at high risk and those
with non–upper-lobe emphysema and high base-line
exercise capacity are poor candidates for lung-volume–
reduction surgery, because of increased mortality and
negligible functional gain.
LVRS

Patient Selection
◦ A systematic review proposed the
following features, as determined by
expert opinion, to be associated with
better outcomes:
 Smoking-related emphysema
 Heterogeneous emphysema with surgically
accessible "target" areas
 Bilateral surgery
 Good general fitness/condition and thoracic
hyperinflation
LVRS
Patient Selection
Endo-bronchial Valves

Endo-bronchial valves (EBV) are one-way
valves that prevent air from entering the
airway distally but allow for ventilation of the
expired gas and drainage of distal secretions.

Two-valve designs have been studied in
separate multicenter reports (Zephyr EBV,
Pulmonx Corp and IBV, Spiration, Inc.).
The Zephyr EBV

The Zephyr EBV, formerly known as Emphasys EBV,
consists of a stent-like self-expanding retainer made
of nitinol, which is wrapped in molded silicone.

In the center of the retainer is a duckbill one-way
valve that allows outflow of gas and secretions during
exhalation but does not permit air entry during
inhalation.

The EBV is compressed via a loader system, placed
onto a delivery catheter, and a guide-wire directs this
catheter to the targeted area, all via the working
channel of a bronchoscope.
The Zephyr EBV
N Engl J Med 2010; 363:1233-1244September 23, 2010DOI: 10.1056/NEJMoa090092
Zephyr EBV, VENT

The EBV valve was tested in The Endo-bronchial
Valve for Emphysema Palliation Trial (VENT).

A multicenter, randomized controlled trial of 321
subjects with severe heterogeneous emphysema
(220 treated with Zephyr EBV and 101 treated as
controls).

At 6-month follow-up, the treatment group had
statistically significant improvements in the
primary endpoints of FEV1
 (+6.8%,P=.002 ) and 6MWT (+5.8%,P=.019 ).
Zephyr EBV, VENT

There were also significant improvements in
secondary outcomes of St. George’s
Respiratory Questionnaire (SGRQ) and
BODE index compared with control.

The 6-month mortality was 2.8% among the
treatment group (zero in the control group),
and cumulative mortality rate over 1-year
follow-up was 3.7% for the Zephyr group
and 3.5% for the control group (P=1.000).
Zephyr EBV, VENT

Complications related to the device were
◦ Valve migration
◦ Pneumonia distal to the valve
◦ Granulation tissue

In final review of various outcomes from this
trial
◦ The FDA advisory panel recommended
against approval of this device, citing that
the benefits were not large enough to
overcome the risks.
IBV, Spiration

The Intrabronchial Valve (IBV;
Spiration) is also made of nitinol
and has 5 distal anchors and 6
proximal support struts that are
covered by a synthetic
polyurethane polymer

These struts expand to form an
umbrella shape to allow for
sealed placement in the airway.

Air and mucus are able to flow
around the edges of the
membrane. The valve has two
delivery system options via a
loading device through the
working channel of a flexible
bronchoscope.
Spiration IBV
The largest trial reported




An open-label study.
A total of 98 patients were enrolled at 13 international
centers over a 3-year period with the intent of bilateral
treatment of upper lobe predominant emphysema.
Bilateral treatment was done in 95 of the 98 patients,
and a total of 659 valves were placed.
While they did not find statistically significant
improvements in spirometry and lung volume
measurements at 3 and 6 month follow-up, the patients
SGRQ decreased by greater than 4 (a 56%
improvement) at 6 months.
Spiration IBV

There were a total of 8 pneumothoraces, one of which was a
tension pneumothorax that occurred on post-procedure day
4 and resulted in the death of the patient.

There were no episodes of valve migration or expectoration.

The most common post-procedure adverse event was
bronchospasm, which resolved after one bronchodilator
treatment in 3 cases but required several repeated
treatments in 2 other patients.

In the latter two cases, the bronchospasm lasted for 24 to 48
hours, resolved after valve removal, and was assumed to be
related to the valves.
Current status of bronchoscopic lung
volume reduction with endo-bronchial
valve

Methods
◦ Searches for appropriate studies were undertaken on
PubMed and Clinical Trials Databases using the search
terms COPD, emphysema, lung volume reduction and
endobronchial valves
Thorax. 2014 Mar;69(3):280-6. doi: 10.1136/thoraxjnl-2013-203743. Epub 2013 Sep 5. Current status of
bronchoscopic lung volume reduction with endobronchial valves. Shah PL1, Herth FJ.
Current status of bronchoscopic lung
volume reduction with endo-bronchial
valve

Results
◦ The evidence from the randomized clinical trials suggests that complete
lobar occlusion in the absence of collateral ventilation or where there is
an intact lobar fissure are the key predictors for clinical success.
◦ Other indicators are greater heterogeneity in disease distribution
between upper and lower lobes
◦ The proportion of patients that respond to treatment
improves from 20% in the unselected population to 75% with
appropriate patient selection
◦ The safety profile for endobronchial valves in this severely affected
group of patients with emphysema was acceptable and the main adverse
events observed were an excess of pneumothoraces.
Thorax. 2014 Mar;69(3):280-6. doi: 10.1136/thoraxjnl-2013-203743. Epub 2013 Sep 5. Current status of bronchoscopic
lung volume reduction with endobronchial valves. Shah PL1, Herth FJ.
Current status of bronchoscopic lung
volume reduction with endo-bronchial
valve

Conclusion
◦ Selected patients have the potential of significant benefit in terms
of lung function, exercise capacity and possibly even survival
◦ These considerations are essential in-order to maximize patient
benefit in a resource-limited environment and also to ensure
that beneficial treatments are available for the appropriate
patient
Thorax. 2014 Mar;69(3):280-6. doi: 10.1136/thoraxjnl-2013-203743. Epub 2013 Sep 5. Current status of bronchoscopic lung volume reduction with
endobronchial valves. Shah PL1, Herth FJ.

This article describes first experiences in a patient with five
endobronchial valves in the right upper lobe who needed urgent
surgery due to lumbar disc herniation with neurological
impairment.

The use of broncho-dilating volatile anesthetics and adjusting the
ventilatory settings with long expiration times and low peak
pressure in a pressure controlled mode seems favorable in these
patients.

In conclusion the care of patients with implanted endobronchial
valves after ELVR does not differ from COPD patients without
ELVR.
COPD
Assessment of General operative risk

Methodologies of
Assessment
◦ Essential components of
the preoperative
assessment are a
 careful history
 physical examination
 assessment of the
functional capacity
Close attention should be
paid to a history of smoking,
dyspnea, cough and sputum
production.
Functional capacity can be
assessed by the ASA
questionnaire
COPD
Assessment of General Operative Risk

The perioperative risk of venous thromboembolism and potential
prophylactic strategies should be assessed for all patients.

In patients with a known diagnosis of COPD, or those at increased
risk for COPD, preoperative spirometry should be performed.
◦ Identification of severe airflow obstruction may be particularly
important in patients who are candidates for upper abdominal or
thoracic surgical procedures

Analysis of arterial blood gas (ABG) composition should be
available for patients with moderate-to-severe COPD.

Since patients with COPD are at increased risk of pulmonary
neoplasm and other pathologies, a preoperative chest radiography,
if not recently performed, is reasonable
Surgery in the COPD Patient

Ophthalmologic procedures
◦
◦
low mortality rate (<1%)
cough may be of concern because of increased ocular pressure.

◦

Procedures involving the airway carry an increased risk of postoperative pneumonia
Management of secretions in the patient who has undergone laryngectomy may require
early postoperative humidification.
Orthopaedic procedures
◦
◦

Topical, ophthalmologic, β-blocker medications, used to reduce intraocular pressure, may
precipitate bronchospasm and cardiorespiratory failure
Head/neck procedures
◦
◦

excessive suppression of cough may lead to retained secretions, atelectasis, pneumonitis and problems
in gas exchange.
Orthopedic procedures are associated with a relatively high frequency of venous
thromboembolism
In the patient with COPD, pulmonary embolism is associated with greater mortality
Lower abdominal/pelvic surgery
◦
In general, COPD does not increase the risk of perioperative risk with lower abdominal
procedures.
Surgery in COPD Patient

Upper abdominal surgery
◦ Patients who undergo surgery in the upper abdomen are at risk for perioperative
pulmonary complications
◦ COPD independently increases this risk
◦ Complications are particularly liable to occur in persons with predisposing factors
such as morbid obesity, cigarette smoking, heart disease and advanced age

Cardiovascular surgery
◦ COPD is a common cause of perioperative pulmonary dysfunction in patients
undergoing cardiac surgery
◦ Screening for COPD in this patient population is particularly important because
COPD has been associated with prolonged intubation after cardiac surgery

Abdominal vascular surgery
◦ Patients who undergo elective major abdominal vascular surgery are at high risk of
postoperative pulmonary complications
◦ Patients with COPD are at particularly high risk
◦
Factors associated with the need for prolonged mechanical ventilation include a
history of heavy cigarette smoking, preoperative arterial hypoxaemia and major
intraoperative blood loss
Surgery in COPD patient

Lung surgery
◦ Preoperative pulmonary function studies have a welldocumented role in the evaluation of patients who are
to undergo lung surgery

Procedure-related issues
◦ Thoracotomy has a reversible (several months)
adverse effect on lung function
◦ Lung resection
 Lobectomy results in an additional ?10% reduction
in forced vital capacity (FVC) at 6 months after
surgery
 Pneumonectomy usually causes a permanent
reduction of about 30% in all lung function. This
decrement in lung function can prove devastating to
COPD patients
COPD and Lung Resection

Patients with preserved lung function should tolerate resection well in the
absence of other comorbid conditions.

Preoperative values of forced expiratory volume in one second (FEV1) >2
L (or >80 percent predicted) and DLCO >80 percent predicted suggest
that the patient should be able to tolerate surgery including
pneumonectomy.

For patients with preoperative FEV1 <2 L (or <80 percent predicted) or
DLCO <80 percent predicted, the predicted postoperative (PPO) FEV1
and DLCO should be calculated, based upon the preoperative values and
the fractional functional contribution of the lung to be resected.
◦ PPO FEV1 = preoperative FEV1 x (1 – y/z)
where y = number of functional or unobstructed lung segments to
be removed, and z = total number of functional segments (typically
19)
COPD and Lung Resection

Cardiopulmonary exercise testing (CPET) is useful when the results of PPO
FEV1, PPO DLCO, and/or low technology exercise testing do not clearly define
the patient’s risk as either high or low.

Patients who can achieve a VO2 max >20 mL/kg per minute are likely to have
an acceptable rate of postoperative complications, whereas those with a value
<10 mL/kg per min (or less than 35 percent predicted) are probably best
managed by nonsurgical modalities.

For those with VO2 max values in between 10 and 20 mL/kg per minute, the
predicted postoperative (PPO) VO2 max is calculated. If the PPO VO2 max is
<10 mL/kg per min or <35 percent, surgical candidacy is poor and
nonresectional options should be sought. On the other hand, if the PPO VO2
max is ≥10 mL/kg per min or ≥35 percent, resection is not absolutely
contraindicated, but the patient must understand the higher risk if either the
PPO FEV1 or DLCO is <30 percent predicted.
Peri-operative Management

General factors include the following.
◦ Every effort should be made to aid with smoking cessation Smoking
cessation at least 4-8 weeks preoperatively is optimal.
◦ Optimization of lung function using inhaled bronchodilators (in
patients with severe COPD can decrease postoperative
complications.
◦ Oral Corticosteroids.

Pulmonary rehabilitation should be
considered in high-risk patients undergoing
elective procedures.
◦
Pre- and postoperative pulmonary rehabilitation have been shown
to decrease postoperative pulmonary complications after abdominal
surgery
Intra-operative Management

The COPD patient may be more sensitive to the ventilatory
depressant effects of the analgesic, regional and general anaesthetic
agents used .

Volatile anesthetics, intravenous anaesthetics and neuromuscular
blocking agents vary in their ability to provoke unwanted
autonomic effects and alter airway reactivity .

The risk of pulmonary complications may be higher with the use of
the long-acting neuromuscular blocker pancuronium than shorteracting atracurium or vecuronium
Intraoperative Management

The role of general versus regional anaesthesia remains
controversial.

A meta-analysis suggested that neuroaxial blockade with
epidural or spinal anaesthesia decrease postoperative
mortality, deep venous thrombosis, pulmonary embolism,
transfusion requirements, pneumonia and respiratory
depression

A subsequent randomized trial of intraoperative and
postoperative epidural analgesia plus general anaesthesia for
upper abdominal surgery in high-risk patients (7-8% with
severe COPD) noted only a reduction in postoperative
respiratory failure (number needed to treat to prevent one
episode of respiratory failure was 15).
Intraoperative Management

In COPD patients, the combination of thoracic epidural
and general anesthesia may result in less shunting and
better oxygenation during thoracic surgical procedures.

Thoracic epidural anaesthesia appears to have only
limited deleterious effects on pulmonary function in
patients with severe COPD and has been used as the
primary mode of anaesthesia for COPD patients
undergoing chest wall surgery .

The immediate postoperative recovery period is a
period of high risk because of the possibilities of
respiratory muscle dysfunction, acidemia, hypoxaemia
and hypoventilation.
Postoperative Management

Early mobilization, deep breathing, intermittent positive-pressure breathing
or incentive spirometry have been reported to decrease postoperative
complications after upper abdominal surgery.

A necessary component of postoperative management is effective
analgesia.
◦ Epidural administration may offer superior analgesia with less sedation by promoting patient
mobility and deep breathing .

Indications for postoperative mechanical ventilation are respiratory failure
with retained secretions, atelectasis and pneumonia.

Continuation of preoperatively prescribed respiratory medications is
standard therapy.
Postoperative Management

Weaning from mechanical ventilation patients with COPD
who have had cardiac surgery may be prolonged

The patient should be ventilated at a level that maintains
arterial carbon dioxide tension at the preoperative level with
a normal pH.

In the COPD patient who is difficult to extubate, gradual weaning
may permit the patient’s cardiovascular status to become
sufficiently stable to tolerate assumption of the full work of
breathing
Thank you
References






R. Buhl and S. G. Farmer, “Future directions in the pharmacologic therapy of chronic
obstructive pulmonary disease,” Proceedings of the American Thoracic Society, vol. 2, no. 1,
pp. 83–93, 1995.View at Publisher · View at Google Scholar · View at PubMed · View at
Scopus
T. E. Albertson, S. Louie, and A. L. Chan, “The diagnosis and treatment of elderly patients
with acute exacerbation of chronic obstructive pulmonary disease and chronic
bronchitis,” Journal of the American Geriatrics Society, vol. 58, no. 3, pp. 570–579, 2010.
View at Publisher · View at Google Scholar · View at Scopus
R. De Marco, S. Accordini, I. Cerveri et al., “Incidence of chronic obstructive pulmonary
disease in a cohort of young adults according to the presence of chronic cough and
phlegm,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 1, pp.
32–39, 2007.View at Publisher · View at Google Scholar · View at PubMed · View at
Scopus
Global Initiative for Chronic Obstructive Lung Disease, “Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary disease,” NHLBI/WHO
Workshop Report, National Heart, Lung, and Blood Institute, Bethesda, Md, USA, 2001,
http://www.goldcopd.com/.
U.S. Environmental Protection Agency, “Chronic obstructive pulmonary disease prevalence
and mortality,” December 2009, http://cfpub.epa.gov/eroe/index.
A. Jemal, E. Ward, Y. Hao, and M. Thun, “Trends in the leading causes of death in the United
States, 1970–2002,” Journal of the American Medical Association, vol. 294, no. 10, pp. 1255–
1259, 2005.View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
References








D. M. Mannino, D. M. Homa, L. J. Akinbami, E. S. Ford, and S. C. Redd, “Chronic obstructive pulmonary
disease surveillance–United States, 1971-2000,” Morbidity and Mortality Weekly Report, vol. 51, no. 6,
pp. 1–16, 2002.
Centers for Disease Control, “Deaths from chronic obstructive pulmonary disease, United States 2000–
2005,” Morbidity and Mortality Weekly Report, vol. 57, no. 45, pp. 1229–1232, 2008.
N. R. Anthonisen, M. A. Skeans, R. A. Wise, J. Manfreda, R. E. Kanner, and J. E. Connett, “The effects of a
smoking cessation intervention on 14.5-year mortality: a randomized clinical trial,” Annals of Internal
Medicine, vol. 142, no. 4, pp. 233–239, 2005.
R. L. Berger, M. M. DeCamp, G. J. Criner, and B. R. Celli, “Lung volume reduction therapies for advanced
emphysema: an update,” Chest, vol. 138, no. 2, pp. 407–417, 2010. View at Publisher · View at Google
Scholar
P. M. A. Calverley, J. A. Anderson, B. Celli et al., “Salmeterol and fluticasone propionate and survival in
chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 356, no. 8, pp. 775–
789, 2007. View at Publisher · View at Google Scholar · View at PubMed
D. P. Tashkin, B. Celli, S. Senn et al., “A 4-year trial of tiotropium in chronic obstructive pulmonary
disease,” The New England Journal of Medicine, vol. 359, no. 15, pp. 1543–1554, 2008. View at Publisher ·
View at Google Scholar · View at PubMed
B. Celli, M. Decramer, S. Kesten, D. Liu, S. Mehra, and D. P. Tashkin, “Mortality in the 4-year trial of
tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease,” American Journal of
Respiratory and Critical Care Medicine, vol. 180, no. 10, pp. 948–955, 2009. View at Publisher · View at
Google Scholar
C. Vogelmeier, P. Kardos, S. Harari, S. J. M. Gans, S. Stenglein, and J. Thirlwell, “Formoterol mono- and
combination therapy with tiotropium in patients with COPD: a 6-month study,” Respiratory Medicine,
vol. 102, no. 11, pp. 1511–1520, 2008. View at Publisher · View at Google Scholar · View at PubMed ·
View at Scopus
COPD and Pulmonary Hypertension


One of the well-known complications of COPD is
pulmonary hypertension (PH).
Pulmonary Hypertension is defined as
◦ Mean pulmonary artery pressure (PAP) of > 20mmHg at rest,
which is different from the standard definition of pulmonary
arterial hypertension (PAH) defined as a mean PAP>25mmHg.
However in some recent studies, PH secondary to COPD was
defined using the latter standard.

The exact prevalence of pulmonary hypertension resulting
from COPD remains unknown.

A few studies based on hospitalized patients have estimated
the prevalence of PH secondary to COPD as defined by a
mean PAP >20 mmHg to range between 35% and 90%.
COPD and Pulmonary Hypertension

The mechanisms of development of PH in COPD patients include
◦ increase in pulmonary vascular resistance secondary to alveolar hypoxia
◦ increase in pulmonary capillary wedge pressure during exercise in
patients with severe emphysema and hyperinflation.

PH in COPD patients can be divided into two main features,
◦ The first one occurring at rest in the setting of stable COPD. The
majority of these patients will have a mild degree of PH with an average
mean PAP of 25 to 30 mmHg. However if the mean PAP is >40 mmHg,
it is usually associated with cardiopulmonary disease, acute
exacerbation, or disproportionate PH which will be discussed
separately.
◦ The second feature includes worsening of PH during exercise, sleep or
COPD exacerbation.
COPD and Pulmonary Hypertension

Worsening of PH with a marked increase in mean PAP is noted in
patients with advanced COPD and PH at rest.

In these patients, a mean PAP of 25 mmHg during rest may
increase to 50 to 60 mmHg during 30 to 40 watt exercise, sleep or
acute COPD exacerbations, which lead to symptoms of dyspnea on
even daily activities like climbing or walking
COPD and Pulmonary Hypertension

Right heart catheterization (RHC) remains the gold standard
for diagnosis of PH in these patients

RHC can be performed at rest, during steady-state exercise,
and after therapeutic interventions (vasodilators)

There are no clear guidelines regarding indications of
treatment of PH in COPD patients

The necessity of treatment of mild or moderate PH in these
patients remain questionable, however some may argue that
acute increase in PAP with worsening of PH during acute
COPD exacerbations and/or exercise may contribute to
development of right-sided heart failure.
COPD and Pulmonary Hypertension

Prior to initiation of treatment, all patients must have
RHC to evaluate PH severity and to rule out other
explanations for dyspnea such as left sided heart failure.

Treatment may include oxygen therapy and pulmonary
vasodilators.

Long-term oxygen therapy should be prescribed as
clinically indicated since it has been shown to reverse
and /or stabilize PH over a period of 2 to 6 years.
COPD and Pulmonary Hypertension

PAH specific medical therapy including prostacyclin
analogues, phosphodiesterase-5 inhibitors and endothelin
receptor antagonists were tested in randomized controlled
trials, leading to approval of several drugs.

However a recent study included COPD patients with mild
resting PH or no PH treated with Bosentan or placebo
showed no improvement in pulmonary hemodynamics but a
worsening of gas exchange abnormalities.
Thank You